Clinical Trials on Refractory Fallopian Tube Carcinoma

Total 952 results

Memorial Sloan Kettering Cancer Center
Mayo Clinic; University of Chicago; University of Pittsburgh; Baptist Health South... and other collaborators

Active, not recruiting

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cancer | Fallopian Tubes Cancer

United States
University of Pittsburgh
Sanofi

Completed

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Gynecologic Oncology Group

Completed

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Beth Israel Deaconess Medical Center
Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech, Inc.

Terminated

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Serous Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Daiichi Sankyo, Inc.

Completed

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
GOG Foundation
GlaxoSmithKline

Recruiting

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (HOTT)

Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer | Stage III Ovarian Cancer | Stage III Primary Peritoneal Cancer | Stage III Fallopian Tube Cancer

United States
AGO Study Group
Cancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... and other collaborators

Completed

Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOPIII)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Spain, France, Denmark, Belgium, Germany, Austria, China, Italy, Korea, Republic of, Norway, Sweden, United Kingdom
Warwick Medical School

Unknown

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
Fox Chase Cancer Center
National Cancer Institute (NCI)

Withdrawn

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Serous Cystadenocarcinoma | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Ovarian Germ Cell Tumor | Ovarian Papillary Serous Carcinoma | Recurrent Fallopian Tube Cancer

United States
University of Washington
GlaxoSmithKline

Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic... and other conditions

United States
Jonsson Comprehensive Cancer Center
TetraLogic Pharmaceuticals; California Institute for Regenerative Medicine... and other collaborators

Withdrawn

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma

United States
Universitaire Ziekenhuizen KU Leuven
European Commission

Completed

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (EUDARIO)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Germany, Belgium, Italy, Austria, France
New Mexico Cancer Care Alliance

Active, not recruiting

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
ImmunoGen, Inc.

Completed

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (SORAYA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Belgium, Spain, Israel, Australia, Ireland, Germany, Italy, Bulgaria, Czechia, Poland
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber... and other collaborators

Active, not recruiting

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Mount Vernon Cancer Centre at Mount Vernon Hospital

Unknown

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Cervical Cancer

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Susana M. Campos, MD
Massachusetts General Hospital; Wyeth is now a wholly owned subsidiary of Pfizer and other collaborators

Completed

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Peritoneal Cancer

United States
Beth Israel Deaconess Medical Center

Completed

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

United States
CanariaBio Inc.
Veristat, LLC

Active, not recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Epithelial Cancer of Ovary | Recurrent Epithelial Ovarian Cancer | Recurrent Carcinoma of Ovary | Adenocarcinoma of Ovary

United States
CanariaBio Inc.
Gynecologic Oncology Group; Iqvia Pty Ltd

Active, not recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Peritoneal Carcinoma | Peritoneal Cancer | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma

Korea, Republic of, United States, Taiwan, Czechia, Argentina, Spain, Belgium, Brazil, Chile, Canada, Italy, Hungary, India, Mexico
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
Uppsala University Hospital
Norrlands Universitetssjukhus, Umea, Sweden

Recruiting

Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test (FOLL-OV)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Sweden
Shanghai Yunying Medical Technology
Shanghai 10th People's Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

China
Lee's Pharmaceutical Limited

Not yet recruiting

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Geoff Hall
National Health Service, United Kingdom

Completed

LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Gynaecological Malignancy

United Kingdom
Turku University Hospital

Active, not recruiting

Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (Mupet)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Finland
City of Hope Medical Center

Completed

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Floyd & Delores Jones Cancer Institute at Virginia...

Completed

Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University of Minnesota
United States Department of Defense

Completed

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
North Eastern German Society of Gynaecological...
Clovis Oncology, Inc.; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Active, not recruiting

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (MAMOC)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Clear Cell Carcinoma

Germany
National Cancer Institute (NCI)

Completed

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Adult Solid Neoplasm

United States, Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota
Celgene Corporation

Terminated

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Merck Sharp & Dohme LLC

Completed

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer
AGO Research GmbH
GlaxoSmithKline

Not yet recruiting

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Primary Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer

Clinical Trials on Refractory Fallopian Tube Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations